The UMCC has had continuing growth of its scientific and clinical relationships with CALGB. UMCC faculty participate in CALGB scientific and administrative committees. UMCC faculty design, conduct and chair many group studies and enter large numbers of patients (pts) onto CALGB studies. There has been greater than 40% growth in our accrual over the last 4 years. UMCC faculty sit on the core committees and chair the Acute Leukemia. UMCC sponsors the MCD CCOP, the Baltimore VA Medical Center (BVAMC), participating local physicians and the Vince Lombardi Cancer Center (VLCC). Funding to continue these activities will allow further growth in the scientific and administrative participation of UMCC and its affiliates in the group. UMCC phase I studies (2 - 4 per year) frequently evolve into group phase II studies. UMCC pilot studies (often performed with other CALGB institutions) have formed the conceptual basis for groupwide studies in leukemia, breast cancer and lung cancer. UMCC is one of the largest accruing institutions for leukemia and one of the largest accruing institutions overall. Our basic science laboratories studying acute leukemia, cellular, animal and clinical pharmacology, and cellular and molecular biology as well as the basic science laboratories of the VLCC, form an important correlative science resource for the group. UMCC and its collaborating institutions (BVAMC, MCD, participating physicians, and VLCC) propose to further our accrual beyond 300 entries per year onto CALGB studies. Participation in CALGB studies will allow UMCC and its affiliated physicians greater treatment options for patients with diseases under study by the group. The recent addition of three surgeons from UMCC to CALGB will further increment the main member institutional accrual. Ancillary studies in UMCC and VLCC laboratories in leukemia, small cell lung cancer, breast cancer and lymphoma will be of particular importance for correlative science. This grant will allow UMCC to continue its highly effective scientific and administrative participation in the group and will continue to allow us to develop a scientific base in the greater Baltimore/Washington area. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and CALGB.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA031983-14
Application #
2088277
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-04-01
Project End
1998-03-31
Budget Start
1995-06-01
Budget End
1996-03-31
Support Year
14
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33
Jaklitsch, Michael T; Gu, Lin; Demmy, Todd et al. (2013) Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. J Thorac Cardiovasc Surg 146:9-16
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Edelman, Martin J; Shvartsbeyn, Marianna (2012) Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer 13:171-80

Showing the most recent 10 out of 102 publications